Efficacy and Safety of Polymer-Free Ultrathin Strut Sirolimus-Probucol Coated Drug-Eluting Stents for Chronic Total Occlusions: Insights from the Coroflex ISAR 2000 Worldwide Registry

Table 5

Clinical outcomes.

Variable	Patients, n (%)	<25 mm lesion length, n (%)	≥25 mm lesion length, n (%)	value
Number of patients	111 (100%)	49 (44.1%)	62 (55.8%)	—
Patients with clinical follow-up at 9 months or early event	101 (91.0%)	46 (93.6%)	55 (88.7%)	0.345
Follow-up time (months)	8.7 ± 2.5	8.1 ± 2.2	9.2 ± 2.6	0.020
Time to discharge median (IQR) (days)	4.5 ± 16.5	3.2 ± 5.7	5.6 ± 21.7	0.45
In-hospital MACE	1 (1.0%)	0 (0.0%)	1 (1.8%)	0.358
In-hospital TLR	0 (0.0%)	0 (0.0%)	0 (0.0%)	—
In-hospital MI	1 (1.0%)	0 (0.0%)	1 (1.8%)	0.358
In-hospital cardiac death	0 (0.0%)	0 (0.0%)	0 (0.0%)	—
9-month MACE	6 (5.9%)	2 (4.3%)	4 (7.3%)	0.536
9-month TLR (Re-PCI/CABG)	2 (2.0%)	1 (2.2%)	1 (1.8%)	0.898
9-month MI	2 (2.0%)	0 (0.0%)	2 (3.6%)	0.191
9-month death all causes	3 (3.0%)	1 (2.2%)	2 (3.6%)	0.666
9-month accumulated definite/probable stent thrombosis	0 (0.0%)	0 (0.0%)	0 (0.0%)	—
Acute stent thrombosis, ≤24 hours	0 (0.0%)	0 (0.0%)	0 (0.0%)	—
Subacute stent thrombosis, 1–30 days	0 (0.0%)	0 (0.0%)	0 (0.0%)
Late stent thrombosis, ≥30 days	0 (0.0%)	0 (0.0%)	0 (0.0%)
BARC 1–5	6 (5.9%)	1 (2.2%)	5 (9.1%)	0.143
BARC 2–5	2 (2.0%)	0 (0.0%)	2 (3.6%)	0.191
BARC 3–5	0 (0.0%)	0 (0.0%)	0 (0.0%)	—